Calcimusc use in allergic diseases is best described by which statement?

• A. It is undoubted because of the precise clinical evidences.
• B. It follows elaborated protocols.
• C. It is suggested, and has to be chosen first medicine.
• D. It can give the doctor and the patient false safety feeling.

Answer: (D)

In allergic diseases, treatments must be guided by solid evidence of benefit. A product like Calcimusc, if its clinical efficacy isn’t demonstrated by robust trials, can give both the doctor and the patient a false sense of safety. This happens because symptom relief or the mere act of taking something can feel soothing, even though it doesn’t address the underlying inflammatory processes of allergy or replace proven therapies such as antihistamines, intranasal corticosteroids, or immunotherapy. Relying on a non-evidence-based remedy can delay appropriate treatment, lead to under-treatment of the actual disease, and make people think they’re protected when they’re not.

So the best description is that it can give the doctor and the patient a false safety feeling.